Product Name :
CMLD012612
Description:
CMLD012612 is an amidino-rocaglate containing a hydroxamate group and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012612 inhibits cell translation and is cytotoxic to NIH/3T3 cells with an IC50 value of 2 nM. CMLD012612 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A) and possesses potent anti-neoplastic activity.
CAS:
2368900-35-8
Molecular Weight:
559.61
Formula:
C31H33N3O7
Chemical Name:
(1R,9R,10S,11R,12R)-12-hydroxy-N,3,5-trimethoxy-9-(4-methoxyphenyl)-N,14-dimethyl-10-phenyl-8-oxa-13,15-diazatetracyclo[7.6.0.0¹,¹².0²,⁷]pentadeca-2,4,6,14-tetraene-11-carboxamide
Smiles :
CC1N[C@@]2(O)[C@@H]([C@@H](C3C=CC=CC=3)[C@@]3(OC4=CC(=CC(OC)=C4[C@@]32N=1)OC)C1C=CC(=CC=1)OC)C(=O)N(C)OC
InChiKey:
GEGBQVSIWBLDJE-GRNIXUCMSA-N
InChi :
InChI=1S/C31H33N3O7/c1-18-32-30-26-23(39-5)16-22(38-4)17-24(26)41-29(30,20-12-14-21(37-3)15-13-20)25(19-10-8-7-9-11-19)27(31(30,36)33-18)28(35)34(2)40-6/h7-17,25,27,36H,1-6H3,(H,32,33)/t25-,27+,29+,30-,31-/m1/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{(-)-Epigallocatechin Gallate} MedChemExpress|{(-)-Epigallocatechin Gallate} Apoptosis|{(-)-Epigallocatechin Gallate} Biological Activity|{(-)-Epigallocatechin Gallate} In Vivo|{(-)-Epigallocatechin Gallate} custom synthesis|{(-)-Epigallocatechin Gallate} Autophagy}
Shelf Life:
≥12 months if stored properly.{{Felzartamab} web|{Felzartamab} CD38|{Felzartamab} Purity & Documentation|{Felzartamab} Purity|{Felzartamab} supplier|{Felzartamab} Autophagy}
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
CMLD012612 is an amidino-rocaglate containing a hydroxamate group and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012612 inhibits cell translation and is cytotoxic to NIH/3T3 cells with an IC50 value of 2 nM. CMLD012612 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A) and possesses potent anti-neoplastic activity.|Product information|CAS Number: 2368900-35-8|Molecular Weight: 559.PMID:24360118 61|Formula: C31H33N3O7|Chemical Name: (1R,9R,10S,11R,12R)-12-hydroxy-N,3,5-trimethoxy-9-(4-methoxyphenyl)-N,14-dimethyl-10-phenyl-8-oxa-13,15-diazatetracyclo[7.6.0.0¹,¹².0²,⁷]pentadeca-2,4,6,14-tetraene-11-carboxamide|Smiles: CC1N[C@@]2(O)[C@@H]([C@@H](C3C=CC=CC=3)[C@@]3(OC4=CC(=CC(OC)=C4[C@@]32N=1)OC)C1C=CC(=CC=1)OC)C(=O)N(C)OC|InChiKey: GEGBQVSIWBLDJE-GRNIXUCMSA-N|InChi: InChI=1S/C31H33N3O7/c1-18-32-30-26-23(39-5)16-22(38-4)17-24(26)41-29(30,20-12-14-21(37-3)15-13-20)25(19-10-8-7-9-11-19)27(31(30,36)33-18)28(35)34(2)40-6/h7-17,25,27,36H,1-6H3,(H,32,33)/t25-,27+,29+,30-,31-/m1/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|The IC50 of CMLD012612 toward NIH/3T3 cells is 2 nM. The primary mechanism of action of CMLD012612 is dependent on eIF4A1, since eIF4A1em1jp cells are at least 10-fold more resistant than parental NIH/3T3 cells. The sensitivity of eIF4A1em1jp cells to CMLD012612 observed at higher concentrations may be due to the presence of wild-type eIF4A2 in the cells.|In Vivo:|CMLD012612 (0.5 mg/kg; intraperitoneal injection; for 3 hours; female C57BL/6 mice) treatment effectively suppresses liver polysomes 3 hours after injection, indicating inhibitory activity toward protein synthesis. When administered to mice bearing myr-Akt/Em-Myc lymphomas, CMLD012612 (0.2 mg/kg; intraperitoneal injection; daily; for 5 days; female C57BL/6 mice) treatment effectively synergizes with Doxorubicin, leading to complete tumor loss.|Products are for research use only. Not for human use.|